WALD

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin's age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously. At the cor

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

3 - Waldencast plc (0001840199) (Issuer)

FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

6-K - Waldencast plc (0001840199) (Filer)

20-F - Waldencast plc (0001840199) (Filer)

6-K - Waldencast plc (0001840199) (Filer)

LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced Schweiger Dermatology as a key partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. Schweiger will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs. "This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and we

NEW YORK and DALLAS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced It's a Secret Med Spa as a key partner in the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. It's a Secret Med Spa will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs. "This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to launching t

NEW YORK and IRVING, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced Aesthetic Record as a key partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. Aesthetic Record will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs, leveraging its seamless EMR, charting, analytics, and integrated tools used by over 9,000 aesthetic clinics. "This partnership with Obagi al

NEW YORK and SUNSET BEACH, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced DermFx as a key partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. DermFx will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs that will highlight the value of ALOHA to DermFx. "This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evid

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced Moxie as a strategic partner in the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. Moxie was selected for its expertise in providing all-in-one software, marketing, coaching, and compliance solutions that help med spa entrepreneurs launch, scale, and optimize their practices with predictable growth, profitability, and a foundation of clinical and operational excellence. Through this real-world evaluation collaboration, Moxie will facilitate a st

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), continues its commitment to advanced skin science with the launch of two new lip innovations designed to work together as a targeted treatment protocol: Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30. Building on the brand's legacy of clinically backed solutions for skin health and rejuvenation, the new Lip Therapy protocol brings Obagi's expertise to one of the most delicate areas of the face. Designed fo

NEW YORK and STRONGSVILLE, Ohio, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced VIO Med Spa as a launch partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. VIO Med Spa was selected for its rapid growth, expert-led approach to advanced aesthetic treatments, and dedication to delivering high-quality, results-driven care across its expanding national network of locations. Through this real-world evaluation collaboration, VIO Med Spa will conduct a structured, multi-site assessment of Obagi® sayp

NEW YORK and LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced Next Health as a key partner in the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. Next Health was selected for its pioneering commitment to longevity, personalized wellness, and cutting-edge aesthetic treatments across its growing network of health optimization centers. Through this real-world evaluation collaboration, Next Health will conduct a structured, multi-site assessment of Obagi® saypha® MagIQ™ within its practices. The p

NEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha was selected as an ALOHA launch partner for its demonstrated commitment to innovation, education, collaboration, and advancing aesthetic medicine through scalable, high-quality care models. Through this real-world evaluation collaboration, Alpha will conduct a structured, multi-site evaluation of Obagi® saypha® Ma